Analyst Price Targets — HOWL
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| December 19, 2025 2:32 pm | — | Wedbush | $1.00 | $0.69 | TheFly | Wedbush downgrades Werewolf Therapeutics to Neutral on challenging path |
| April 3, 2024 2:32 am | Reni Benjamin | JMP Securities | $12.00 | $6.06 | StreetInsider | JMP Securities Starts Werewolf Therapeutics Inc. (HOWL) at Market Outperform, 'PREDATOR Platform Unleashes Cytokine Biology to Kill Cancer' |
Latest News for HOWL
Company continues to evaluate strategic options to maximize shareholder value Company continues to evaluate strategic options to maximize shareholder value
WATERTOWN, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (Nasdaq: HOWL) (the “Company” or “Werewolf”), an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions, today announced that the Company will explore a full range of strategic alternatives to advance…
Shares of Werewolf Therapeutics, Inc. (NASDAQ: HOWL - Get Free Report) have earned a consensus recommendation of "Hold" from the seven research firms that are presently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell rating, four have issued a hold rating and two have issued a buy rating on the
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for HOWL.
U.S. House Trading
No House trades found for HOWL.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.